Increased susceptibility to intensive care unit-acquired pneumonia in severe COVID-19 patients: a multicentre retrospective cohort study.
COVID-19
Immunosuppression
Septic shock
Ventilator-acquired pneumonia
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
29 Jan 2021
29 Jan 2021
Historique:
received:
20
09
2020
accepted:
18
01
2021
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
30
1
2021
Statut:
epublish
Résumé
The aim of this study is to determine whether severe COVID-19 patients harbour a higher risk of ICU-acquired pneumonia. This retrospective multicentre cohort study comprised all consecutive patients admitted to seven ICUs for severe COVID-19 pneumonia during the first COVID-19 surge in France. Inclusion criteria were laboratory-confirmed SARS-CoV-2 infection and requirement for invasive mechanical ventilation for 48 h or more. Control groups were two historical cohorts of mechanically ventilated patients admitted to the ICU for bacterial or non-SARS-CoV-2 viral pneumonia. The outcome of interest was the development of ICU-acquired pneumonia. The determinants of ICU-acquired pneumonia were investigated in a multivariate competing risk analysis. One hundred and seventy-six patients with severe SARS-CoV-2 pneumonia admitted to the ICU between March 1st and 30th June of 2020 were included into the study. Historical control groups comprised 435 patients with bacterial pneumonia and 48 ones with viral pneumonia. ICU-acquired pneumonia occurred in 52% of COVID-19 patients, whereas in 26% and 23% of patients with bacterial or viral pneumonia, respectively (p < 0.001). Times from initiation of mechanical ventilation to ICU-acquired pneumonia were similar across the three groups. In multivariate analysis, the risk of ICU-acquired pneumonia remained independently associated with underlying COVID-19 (SHR = 2.18; 95 CI 1.2-3.98, p = 0.011). COVID-19 appears an independent risk factor of ICU-acquired pneumonia in mechanically ventilated patients with pneumonia. Whether this is driven by immunomodulatory properties by the SARS-CoV-2 or this is related to particular processes of care remains to be investigated.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study is to determine whether severe COVID-19 patients harbour a higher risk of ICU-acquired pneumonia.
METHODS
METHODS
This retrospective multicentre cohort study comprised all consecutive patients admitted to seven ICUs for severe COVID-19 pneumonia during the first COVID-19 surge in France. Inclusion criteria were laboratory-confirmed SARS-CoV-2 infection and requirement for invasive mechanical ventilation for 48 h or more. Control groups were two historical cohorts of mechanically ventilated patients admitted to the ICU for bacterial or non-SARS-CoV-2 viral pneumonia. The outcome of interest was the development of ICU-acquired pneumonia. The determinants of ICU-acquired pneumonia were investigated in a multivariate competing risk analysis.
RESULT
RESULTS
One hundred and seventy-six patients with severe SARS-CoV-2 pneumonia admitted to the ICU between March 1st and 30th June of 2020 were included into the study. Historical control groups comprised 435 patients with bacterial pneumonia and 48 ones with viral pneumonia. ICU-acquired pneumonia occurred in 52% of COVID-19 patients, whereas in 26% and 23% of patients with bacterial or viral pneumonia, respectively (p < 0.001). Times from initiation of mechanical ventilation to ICU-acquired pneumonia were similar across the three groups. In multivariate analysis, the risk of ICU-acquired pneumonia remained independently associated with underlying COVID-19 (SHR = 2.18; 95 CI 1.2-3.98, p = 0.011).
CONCLUSION
CONCLUSIONS
COVID-19 appears an independent risk factor of ICU-acquired pneumonia in mechanically ventilated patients with pneumonia. Whether this is driven by immunomodulatory properties by the SARS-CoV-2 or this is related to particular processes of care remains to be investigated.
Identifiants
pubmed: 33512602
doi: 10.1186/s13613-021-00812-w
pii: 10.1186/s13613-021-00812-w
pmc: PMC7844782
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20Références
Lancet Infect Dis. 2013 Mar;13(3):260-8
pubmed: 23427891
Lancet Infect Dis. 2013 Aug;13(8):665-71
pubmed: 23622939
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
BMC Infect Dis. 2019 Nov 5;19(1):931
pubmed: 31690258
JAMA. 2016 Apr 12;315(14):1469-79
pubmed: 26975785
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Ann Intensive Care. 2019 Jun 13;9(1):69
pubmed: 31197492
JAMA. 2011 Dec 21;306(23):2594-605
pubmed: 22187279
Crit Care Med. 2017 Mar;45(3):486-552
pubmed: 28098591
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
Ann Intensive Care. 2019 Mar 15;9(1):39
pubmed: 30877607
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Intensive Care Med. 2021 Jan;47(1):60-73
pubmed: 33211135
Ann Intensive Care. 2020 Nov 23;10(1):158
pubmed: 33230710
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Intensive Care Med. 2021 Feb;47(2):188-198
pubmed: 33388794
Crit Care. 2020 Dec 18;24(1):699
pubmed: 33339526
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758